Skip to main content

Select Drug Profiles

Perspectives
Ahead of the Curve
David B. Nash, MD, MBA
Read More
Perspectives
Guiding Employer Management of Specialty Drugs
Cheryl Larson, F. Randy Vogenberg, PhD, FASHP
Read More
Practice Management
Trends in Medicare Part D Medication Therapy Management Eligibility Criteria
Junling Wang, PhD, Ya-Chen Tina Shih, PhD, Yolanda Qin, Theo Young, BS, Zachary Thomas, MS, MBA, Christina A. Spivey, PhD, David K. Solomon, BSc, PharmD, Marie Chisholm-Burns, PharmD, MPH, MBA, FCCP, FASHP, J. Warren Salmon, PhD
Stakeholder Perspective
Is It Time to Revisit Medicare Part D?
by J. Warren Salmon, PhD
Read More
Original Research
Value-Based Benefit Design to Improve Medication Adherence for Employees with Anxiety or Depression
Kimberly J. Reid, MS, Kathleen M. Aguilar, MPH, Eric Thompson, MBA, Ross M. Miller, MD, MPH
Stakeholder Perspective
Counting on a Run of Value-Based Benefit Design
by Albert Tzeel, MD, MHSA, CPE, FAAPL
Read More
Practice Management
US Healthcare Annual Spending Estimated to Rise by 5.8% on Average Through 2024
Laura Morgan
Read More
Resource Utilization for Chemotherapy-Induced Nausea and Vomiting Events in Patients with Solid Tumors Treated with Antiemetic Regimens
Lee Schwartzberg, MD, Brooke Harrow, PhD, Lincy S Lal, PharmD, PhD, Janna Radtchenko, MBA, Gary H. Lyman, MD, MPH
Stakeholder Perspective
Impact of Chemotherapy-Induced Nausea and Vomiting Treatment on Patient Outcomes and Resource Utilization
by James T. Kennedy, Jr, RPh, MBA
Read More
Value-Based Healthcare Delivery: The Agenda for Oncology
Chase Doyle
Read More
FDA Approvals
Nivolumab Beats Docetaxel as Second-Line Therapy for Patients with NSCLC
Phoebe Starr
Read More
Searching for the Tipping Point in Drug Pricing
Caroline Helwick
Read More
FDA Approvals
Oncology Pipeline Full, and Not Just with Immunotherapies
Caroline Helwick, Wayne Kuznar
Read More
Page 127 of 244
Results 1261 - 1270 of 2434